柏诚系统科技股份有限公司 2025 年第三季度报告 证券代码：601133 证券简称：柏诚股份 柏诚系统科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 注："本报告期"指本季度初至本季度末 3 个月期间，下同。 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 | 非经常性损益项目 | 本期金额 | 年初至报告 期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损益，包括已计提资产减值准备的冲销 | -220.75 | -45,280.52 | | ...

Core Insights - The company reported a significant decline in revenue and net profit for the third quarter and the first three quarters of the year [1] Financial Performance - Third quarter revenue was 853 million yuan, a year-on-year decrease of 36.16% [1] - Third quarter net profit was 49.46 million yuan, a year-on-year decrease of 16.41% [1] - Revenue for the first three quarters was 3.276 billion yuan, a year-on-year decrease of 14.63% [1] - Net profit for the first three quarters was 133 million yuan, a year-on-year decrease of 16.22% [1]

Core Viewpoint - The company, 柏诚股份 (601133.SH), has clarified that it currently has no business cooperation relationship with 新凯 [1] Group 1 - 柏诚股份 confirmed the absence of any business collaboration with 新凯来 [1]

Core Viewpoint - The acquisition plan by Baicheng Co., Ltd. (601133) to purchase 55% of Shanghai Canxi Engineering Equipment Co., Ltd. has been terminated due to failure to reach agreement on key terms, leading to the end of the deal just 10 days after its announcement [1][5]. Group 1: Acquisition Details - Baicheng Co. announced the termination of the acquisition plan on October 10, 2023, which had been under consideration since September 30, 2023 [1]. - The company had previously signed an investment cooperation framework agreement with the sellers, which included specific pricing based on a report from a qualified assessment agency [5]. - The termination of the acquisition is stated not to adversely affect the company's business operations, financial status, or shareholder interests [5][6]. Group 2: Financial Performance - Baicheng Co. has experienced a decline in net profit, with a year-on-year decrease of 14.7% in 2023, followed by a further decline of 0.8% in 2024, and a continuation of this trend in the first half of 2025 [6][8]. - The company's revenue for the first half of 2025 was reported at 2.424 billion yuan, a decrease of 3.14% year-on-year, with a net profit attributable to shareholders of 83.4953 million yuan, reflecting a decline of 16.1% [8]. - The primary reason for the profit decline is attributed to an increase in bad debt provisions for contract assets, with asset impairment losses reaching 50.8 million yuan, a significant increase of 55% compared to the same period last year [8].

Core Viewpoint - 柏诚股份 has terminated its plan to acquire 55% of Shanghai Canxi Engineering Equipment Co., Ltd. through a combination of issuing shares and cash payment, leading to the resumption of its stock trading on October 13, 2025 after a suspension since September 30, 2025 [1][2] Group 1: Transaction Details - The company had initially planned to purchase shares from several parties, including Zhou Huajie and others, and to raise additional funds through a share issuance [1] - The termination of the transaction was due to the inability to reach an agreement on key terms between the parties involved, despite ongoing discussions during the suspension period [2] - The company stated that the termination would not adversely affect its business operations or financial status, nor harm the interests of its shareholders, particularly minority shareholders [2] Group 2: Financial Performance - In 2024, 柏诚股份 reported a revenue of 5.24 billion yuan, representing a year-on-year increase of 31.78%, while the net profit attributable to shareholders was 212.26 million yuan, a slight decrease of 0.80% [3][4] - The net profit after excluding non-recurring gains and losses was 204.39 million yuan, down 2.49% from the previous year [4] - For the first half of 2025, the company experienced a revenue decline of 3.14% to 2.42 billion yuan, with a net profit of 83 million yuan, reflecting a 16.10% decrease [5]

Core Viewpoint - The company has terminated the planned acquisition of 55% of Shanghai CanShine Engineering Equipment Co., Ltd., which has drawn market attention, but this decision will not adversely affect its business operations or financial status [1][2]. Group 1: Acquisition Details - The acquisition was aimed at addressing core pain points in the biopharmaceutical sector and enhancing the company's strategic layout in this area [2]. - Shanghai CanShine possesses core capabilities in high-end biopharmaceuticals, including monoclonal antibodies and vaccines, which align well with the company's existing business [2]. - The termination of the acquisition was due to the inability to reach consensus on key terms, reflecting the company's commitment to shareholder interests and prudent decision-making [2][3]. Group 2: Strategic Focus - The company remains committed to its strategic focus in the semiconductor and biopharmaceutical sectors, emphasizing its modular overall solutions that meet overseas biopharmaceutical clients' needs for efficient delivery and compliance [3]. - Continuous investment in independent innovation has led to the establishment of a modular manufacturing base, supporting scalable and standardized development [3]. - The company plans to leverage favorable policies and market conditions to enhance its integrated solutions in biopharmaceutical cleanroom systems and core process systems, aiming to meet evolving customer demands and improve competitive strength [3].

Core Viewpoint - The acquisition plan by Baicheng Co., Ltd. to purchase 55% of Shanghai Canxi Engineering Equipment Co., Ltd. has been terminated due to the inability to reach an agreement on key terms of the transaction within a short period of 10 days [1][3]. Group 1: Acquisition Details - Baicheng Co. announced the termination of the acquisition plan on October 10, following a suspension of trading that began on September 30 [1]. - The company had previously signed an investment cooperation framework agreement with several parties, including Zhou Huajie and Tai Qing, to facilitate the acquisition [3]. - The transaction was not expected to constitute a major asset restructuring or related party transaction, nor would it lead to a change in the actual controller of the company [3]. Group 2: Financial Performance - Baicheng Co. has experienced a continuous decline in financial performance, with a 14.7% decrease in net profit in 2023 and a further 0.8% decline projected for 2024 [4]. - The company's revenue for the first half of 2025 was reported at 2.424 billion yuan, a year-on-year decrease of 3.14%, while the net profit attributable to shareholders fell by 16.1% to 83.4953 million yuan [6]. - The decline in profit is attributed to an increase in the provision for bad debts related to contract assets, with asset impairment losses reaching 50.8 million yuan, a 55% increase compared to the same period last year [6].

Group 1: Innovation in Pharmaceuticals - The State Council has introduced regulations to standardize clinical research and application of biomedical technologies, promoting innovation and ensuring medical quality and safety [1] - The innovative pharmaceutical industry is experiencing positive fundamentals, with overseas licensing amounts exceeding $66.8 billion by mid-2025, and 31% of innovative drugs introduced by international pharmaceutical companies originating from China [1] Group 2: Infrastructure Development - Seven departments, including the Ministry of Industry and Information Technology, have released a plan to enhance new information infrastructure, focusing on the integration of "5G + industrial internet" and the development of computing power infrastructure [2] - The plan aims to promote the resourceization and assetization of industrial data, and to integrate artificial intelligence technologies with service-oriented manufacturing [2] Group 3: Financial Standards - The China Securities Regulatory Commission has published three financial industry standards related to securities exchanges and asset securitization, effective immediately [3] Group 4: Housing and Urban Development - The Ministry of Housing and Urban-Rural Development is deepening reforms in the housing and real estate sectors during the 14th Five-Year Plan, aiming to establish a new model for real estate development and improve the housing supply system [4] Group 5: Healthcare Pricing Regulation - The National Healthcare Security Administration has initiated a special rectification of "dual pricing" practices in designated retail pharmacies, emphasizing the need for fair pricing for insured patients [5][6] Group 6: Cloud Computing Standards - The Ministry of Industry and Information Technology and the National Standardization Administration have issued guidelines for the construction of a comprehensive cloud computing standardization system, aiming to establish over 30 new national and industry standards by 2027 [7] Group 7: Company News - Nengke Technology plans to raise up to 1 billion yuan for the development of its AI training platform [8] - Various companies reported significant year-on-year profit increases, with notable growth from Dao Shi Technology (408.27%) and Dongyangguang (171.08% - 199.88%) [8]

Core Viewpoint - 柏诚股份 has announced the termination of its plan to issue shares and pay cash for the acquisition of assets, leading to the resumption of its stock trading from October 13 [1] Group 1 - On September 29, 柏诚股份 signed an investment cooperation framework agreement with several parties to acquire 55% of Shanghai Can Shi Engineering Equipment Co., Ltd. [1] - The company had planned to issue shares to raise matching funds for this acquisition, but the stock was suspended from trading starting September 30 [1] - The termination of this transaction will not adversely affect the company's business operations, activities, or financial status [1]

Core Viewpoint - The company announced the termination of its plan to acquire a 55% stake in Shanghai CanShih Engineering Equipment Co., Ltd., and its stock will resume trading on October 13, 2025 [1][2]. Group 1: Transaction Details - On September 29, 2025, the company signed a framework agreement to acquire the stake in Shanghai CanShih, intending to issue shares and pay cash [1]. - The company applied for a trading suspension starting September 30, 2025, with a pre-suspension stock price of 13.38 yuan per share, valuing the company at 7.065 billion yuan [1]. - The termination was due to the inability to reach consensus on key terms of the transaction, despite ongoing discussions [2]. Group 2: Company Background - Founded in 1994 and headquartered in Wuxi, Jiangsu Province, the company specializes in cleanroom system integration solutions for high-tech industries [2]. - The company serves key national industries, including semiconductors, life sciences, and new energy, and is one of the few providers capable of handling mainstream projects across multiple sectors [2]. Group 3: Financial Performance - For the first half of the year, the company reported revenue of 2.424 billion yuan, a decrease of 3.14% year-on-year [3]. - As of June 30, 2025, the company had an order backlog of 1.747 billion yuan (excluding tax) [3]. - The net profit attributable to shareholders was 83.4953 million yuan, reflecting a year-on-year decline of 16.10% [3].